Category: Wall Street Beat
HCA Holdings halts the use of laparoscopic power morcellators in uterine fibroid surgeries in all 278 of its facilities, after the FDA raises the warning level on the cancer risk associated with the devices.
(Reuters) — HCA Holdings (NYSE:HCA), the largest for-profit U.S. hospital operator, said a procedure for removing uterine fibroids that's been linked to the spread of cancer will no longer be performed at its facilities.
Medtronic says it expects to repatriate as much as $4 billion in cash after it resolves a dispute with the IRS involving its Puerto Rico subsidiary.
Medtronic (NYSE:MDT) said today that it expects to land a substantial windfall once it resolves a dispute with the IRS over the next "couple of years."
Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.
UPDATED Nov. 24 with analysis from Morgan Stanley.
Second Sight Medical, which yesterday saw its initial public offering close up nearly 122%, could have its next-generation 'bionic eye' device ready for nearly all blind patients 'within a couple of years,' CEO Dr. Robert Greenberg tells MassDevice.com.
Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3
Cardica shares plunge after it suspends the launch of its MicroCutter Xchange 30 surgical stapler so it can focus on improving the product, a move that may also result in a realignment of its operations.
Venture capital investment in medical device companies rose in terms of both value and volume during the 3rd quarter, compared with the same period last year, according to PricewaterhouseCoopers.
Venture capitalists put more cash into more deals for medical device companies during the 3rd quarter, according to a report from PricewaterhouseCoopers.
Medical device companies pulled down $586 million in 78 deals during the 3rd quarter, up 13% in dollars and 18% in deal volume compared with Q3 2013.